Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Vomiting 2Uterine Cervical Neoplasms 2Nausea 2Condylomata Acuminata 2Breast Neoplasms 2Sezary Syndrome 1Renal Insufficiency 1Osteoarthritis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Kidney Failure, Chronic 1Cancer Pain 1Bone Neoplasms 1Adenomatous Polyposis Coli 1

Interventions

Peripheral Blood Stem Cell Transplantation 38fludarabine phosphate 37Cyclophosphamide 33Mycophenolic Acid 28Whole-Body Irradiation 24Cyclosporine 24Tacrolimus 22Radiotherapy 19Methotrexate 18Busulfan 18Antilymphocyte Serum 17Filgrastim 14Etoposide 14Vorinostat 11Bortezomib 11Bexarotene 11Methylprednisolone 10Lenalidomide 10pembrolizumab 9Rituximab 9Melphalan 9Gemcitabine 9Flow Cytometry 9Brentuximab Vedotin 9romidepsin 8mogamulizumab 8Methoxsalen 8fludarabine 7Magnetic Resonance Spectroscopy 7Cord Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mycosis Fungoides × Duration of Therapy × Clear all
NCT00091559 2017-04-05

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Merck Sharp & Dohme LLC

Phase 2 Completed
74 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡